Despite Bleed Problems, Pradaxa Sales Soar

Boehringer Ingleheim’s relatively new anticoagulant Pradaxa has hit blockbuster status, even amid hundreds of deaths and other serious injuries caused by bleeding problems experienced by users of the medication. 

Blockbuster status is a title reserved in the pharmaceutical business industry for medications whose annual sales top $1 billion.

According to a statement issued this week by Boehringer Ingleheim, Pradaxa sales reached $831 million in 2011. However, for the 12 month period ending in February 2012, sales of the drug passed the $1 billion mark.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

Pradaxa (dabigitran) was introduced in the United States in October 2010, and was the frontrunner of a new breed of anticoagulants known as direct thrombin inhibitors, which also now includes Bayer and Johnson & Johnson’s Xarelto, and Eliquis, a Pfizer and Bristol-Myers Squibb drug.

The drug maker has aggressively marketed Pradaxa to physicians and directly to consumers as a replacement for warfarin, an older anticoagulant. Pradaxa has been promoted as superior because it requires less monitoring.

However, within months of the drug’s introduction, concerns emerged about the risk of bleeding problems with Pradaxa, with hundreds of complaints filed with the FDA’s adverse event reporting system (AERS).

According to a report released by the Institute for Safe Medication Practices in January 2012, more instances of bleeding problems with Pradaxa were reported to the FDA during the first quarter of 2011 than were reported in association with any other drug monitored by the group.  At least 505 instances involving Pradaxa bleeding events were reported, compared to 176 cases reported with warfarin, which was second on the list.

While Pradaxa requires less monitoring than warfarin, the medication lacks a quick “antidote” to counteract bleeding problems when they do occur. With warfarin, doctors are able to stop the bleeding with the use of a reversal agent, like a dose of vitamin K. There is no quick fix for Pradaxa.

Pradaxa safety investigations are now underway in the U.S. by the FDA, as well as in the European Union and Canada.

Despite the concerns surrounding the bleeding problems, Boehringer Ingleheim is boasting that the launch of Pradaxa was “among the most successful market introductions in the pharmaceutical industry in the past few years.”

However, the drug maker now faces a growing number of Pradaxa lawsuits brought on behalf of individuals who have suffered serious bleeding problems or death. The complaints allege that Boehringer Ingleheim introduced the medication without adequate warnings about the Pradaxa bleeding risk or the lack of a reversal agent.

0 Comments

"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Bard Argues Hernia Mesh Lawsuits Previously Selected for Bellwether Trials Are No Longer
Bard Argues Hernia Mesh Lawsuits Previously Selected for Bellwether Trials Are No Longer "Representative" (Posted today)

Bard claims two cases selected for the third and fourth bellwether trials are no longer representative of the litigation due to the plaintiffs' worsening injuries and need for additional surgeries due to their failed hernia mesh products.